



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Laura C. Blumberg, et al.

SERIAL NO.: 09/972,177 ✓

:Examiner: Unknown

:Art Unit: 1614

FILED: October 5, 2001

FOR: Bridged Piperazine Derivatives ✓

Assistant Commissioner For Patents  
Washington, D.C. 20231

I hereby certify that this correspondence  
is being deposited with the United States  
Postal Service as First Class Mail in an  
envelope addressed to: Assistant Commissioner  
for Patents, Washington, D.C. 20231 on

this 26<sup>th</sup> day of August 2002

Sir:

By 

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee should be required for this request. If, however, the Commissioner determines that any fee is due please charge it to Deposit Account No. 16-1445. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to deposit Account No. 16-1445. Two copies of this sheet are enclosed.

A prompt and favorable response is earnestly solicited.

Date: 8/26/02

Respectfully submitted,



Lisa A. Samuels

Attorney for Applicant(s)

Reg. No. 43,080

Pfizer Inc.  
Patent Department, Box 8260-1611  
Eastern Point Road  
Groton, CT 06340  
(860) 686-0349